Bezafibrate improves hypertension and insulin sensitivity in humans

Hypertension Research

Volumn 26, Issue 4, 2003, Pages 307-313

  Kim, Jong Il ^a,b   Tsujino, Takeshi ^c   Fujioka, Yoshio ^c   Saito, Komei ^d   Yokoyama, Mitsuhiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hidaka Hospital   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d Saito Clinic   (Japan)

Author keywords

Bezafibrate; Fatty acid; Glucose tolerance; Insulin; Triglyceride

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BEZAFIBRATE; GLUCOSE; MEMBRANE LIPID; PLACEBO; SATURATED FATTY ACID;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CELL MEMBRANE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE SEVERITY; ERYTHROCYTE MEMBRANE; ESSENTIAL HYPERTENSION; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; LIPID COMPOSITION; MALE; METABOLIC DISORDER; ORAL GLUCOSE TOLERANCE TEST; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEINS; BEZAFIBRATE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CELL MEMBRANE; ERYTHROCYTE MEMBRANE; FATTY ACIDS; HEART RATE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE;

EID: 0037649053     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.307     Document Type: Article

References (42)

1. Ferrannini E, Galvan AQ: Hyperinsulinemia, insulin resistance, and blood pressure. Hypertens Res 1992; 15: 67-75.
2. Kawamori R: Insulin resistance seen in non-insulin dependent diabetes mellitus and hypertension. Hypertens Res 1996; 19 (Suppl 1): S61-S64.
3. DeFronzo R, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
4. Fujioka S, Matsuzawa Y, Tokunaga K, et al: Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36: 54-59.
5. Masuzaki H, Ogawa Y, Aizawa-Abe M, et al: Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation: usefulness of leptin for the treatment of obesity-associated diabetes. Diabetes 1999; 48: 1615-1622.
6. Matsuzawa Y, Funahashi T, Nakamura T: Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999; 892: 146-154.
7. Barbier O, Torra IP, Duguay Y, et al: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 717-726.
8. Matsuzawa Y, Shimomura I, Nakamura T, et al: Pathophysiology and pathogenesis of visceral fat obesity. Diabetes Res Clin Pract 1994; 24: S111-S116.
9. Borkman M, Storlien LH, Pan DA, et al: The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N Engl J Med 1993; 328: 238-244.
10. Roden M, Price TB, Perseghin G, et al: Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-2865.
11. Barnett D, Craig JG, Robinson DS, Perenna Rogers M: Effect of clofibrate on glucose tolerance in maturity onset diabetes. Br J Clin Pharmacol 1977; 4: 455-458.
12. Kobayashi M, Shigeta Y, Hirata Y, et al: Improvement of glucose tolerance in NIDDM by clofibrate: randomized double-blind study. Diabetes Care 1988; 11: 195-199.
13. Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KGMM: Lowering of plasma glucose concentrations with bezatibrate in patients with moderately control NIDDM. Diabetes Care 1990; 13: 855-863.
14. Mikhailidis DP, Mathur S, Barradas MA, Dandoma P: Bezafibrate retard in type II diabetes patients: effects of hemostasis and glucose homeostasis. J Cardiovasc Pharmacol 1990; 16 (Suppl 9): 26-29.
15. Inoue I, Takahashi K, Katayama S, et al: Improvement of glucose tolerance by bezafibrate in obese patients with hyperlipidemia and impaired glucose tolerance. Diabetes Res Clin Pract 1994; 25: 199-205.
16. Ogawa S, Takeuchi K, Sugimura K, et al: Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism 2000; 49: 331-334.
17. Furuhashi M, Ura N, Murakami H, et al: Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and β-oxidation in skeletal muscle. J Endocrinol 2002; 174: 321-329.
18. Friedewald WT, Levy RT, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
21. Cederholm J, Wibell L: Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 1990; 10: 167-175.
22. Hanahan DJ, Ekholm JE: The preparation of red cell ghosts (membranes), in Fleisher S, Packer L (eds): Methods in Enzymology, Vol 31. New York, Academic Press, 1974, pp 168-172.
23. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
24. Shohet SB: Haemolysis and changes in erythrocyte membranes. New Engl J Med 1972; 286: 577-579.
25. Renooij W, Van Golde LMG: The exchange of phospholipids between rat erythrocytes and plasma, and the translocation of phosphatidylcholine across the red cell membrane, are temperature-dependent processes. FEBS Lett 1976; 71: 321-324.
26. Kamada T, Yamashita T, Baba Y, et al: Dietary sardine oil increases erythrocyte membrane fluidity in diabetic patients. Diabetes 1986; 35: 604-611.
27. Stubbs CD, Smith AD: The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta 1984; 779: 89-137.
28. Matsui H, Okumura K, Kawakami K, Hibino M, Toki Y, Ito T: Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglycerides. Diabetes 1997; 46: 348-353.
29. Tsuda K, Kinoshita Y, Nishio I, Masuyama Y: Hyperinsulinemia is a determinant of membrane fluidity of erythrocytes in essential hypertension. Am J Hypertens 2001; 14: 419-423.
30. Mills DE, Summers MR, Ward RP: Gammalinoleic acid attenuates cardiovascular responses to stress in borderline hypertensive rats. Lipids 1985; 20: 573-577.
31. + exchanger in fructose-fed borderline hypertensive rats. Hypertens Res 2003; 26: 111-116.
32. Bønaa KH, Bjerve KS, Straume B, Gram IT, Thelle D: Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. N Engl J Med 1990; 322: 195-201.
33. Knapp HR, FitzGerald GA: The antihypertensive effects of fish oil. N Engl J Med 1989; 320: 1037-1043.
34. Miyajima T, Tsujino T, Saito K, Yokoyama M: Effects of eicosapentaenoic acid on blood pressure, cell membrane fatty acids, and intracellular sodium concentration in essential hypertension. Hypertens Res 2001; 24: 537-542.
35. Engler MB, Ma Y-H, Engler MM: Calcium-mediated mechanisms of eicosapentaenoic acid-induced relaxation in hypertensive rat aorta. Am J Hypertens 1999; 12: 1225-1235.
36. McVeigh GE, Brennan GM, Johnston GD, et al: Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 33-38.
37. Abbott WGH, Lillioja S, Young AA, et al: Relationships between plasma lipoprotein concentrations and insulin action in an obese hyperinsulinemic population. Diabetes 1987; 36: 897-904.
38. Robertson DA, Haegerty AM, Ollerenshaw JD, Swales JD: Linoleic acid supplementation, membrane lipids and leukocyte sodium transport in normotensive humans. J Hum Hypertens 1989; 3: 117-123.
39. Corrocher R, Pagnan A, Ambrosio GB, et al: Effects induced by olive oil-rich diet on erythrocytes membrane lipids and sodium-potassium transports in postmenopausal hypertensive women. J Endocrinol Invest 1992; 15: 369-376.
40. Lijnen P, Celis H, Fagard R, Staessen J, Amery A: Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens 1994; 12: 59-64.
41. Roman RJ, Alonso-Galicia M, Wilson TW: Renal P450 metabolites of arachidonic acid and the development of hypertension in Dahl salt-sensitive rats. Am J Hypertens 1997; 10(Suppl): 63S-67S.
42. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316-320.